Program: Oral and Poster Abstracts
Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster I
Methods:
Patients: We performed a retrospective IRB-approved analysis of patients diagnosed with FL 3A, 3B, or FL3 with concomitant areas of DLBCL. 72 subjects were identified with FL grade 3; including: 3A, 3B, FL 3/DLBCL, or unclassified FL3. We excluded subjects who had no follow-up data or diagnosed as unclassified FL 3, thus we analyzed a cohort of 46 patients. These 46 were divided into two groups. The aggressive lymphoma group (n=21) included subjects diagnosed with FL3B (n=11) and FL3 (A or B) with concomitant areas of DLBCL (n=10) (termed aggFL). The indolent lymphoma group (n=25) included subjects diagnosed with FL3A. All patients started their 1st treatment between 1998-2014. The aim of this study was to assess the clinical outcomes by comparing the progression free survival (PFS) and overall survival (OS) between the two groups.
Results: Of the 46 patients, 25 (54%) had FL 3A, 11 (24%) FL 3B, and 10 (22%) FL3/DLBCL. Thus, the aggressive group (aggFL) had 21 patients (46%). For the entire cohort, 37 (49%) were male and 35 (51%) female; 78% were Caucasian. Table 1 compares FL 3A and combined 3B and FL 3/DLBCL cohorts.
With median follow-up of 54 and 62 months for FL3A and aggFL, respectively; 75% of FL 3A and 86% of aggFL patients were alive. Among the FL3A and combined aggFL groups, 23 of 25 (92%) and 18 of 21patients (85%) received R-CHOP, respectively. There was no statistical difference in PFS between the 2 groups, and each group has apparent PFS plateau after ~ 3 years (Figure2). Similarly, we found that no statistical difference in Overall Survival between the groups of indolent FL (F3A) and aggFL (FL3B or FL3/DLBCL) lymphoma.
Conclusion: The outcomes of the 1st large series of FL grade 3 patients in the rituximab era, primarily treated with R-CHOP, show no statistically significant difference in PFS or OS between FL 3A vs. aggFL with predominantly large cells (FL 3B/DLBCL). As expected, aggFL, FL3B and FL3/DLBCL, showed a plateau confirming that these pts should be treated with curative intent. Surprisingly, FL3A pts mainly managed with R-CHOP also show a plateau in survival; however, indicating the possibility of long term unmaintained remission in this histology and raising the issue of potential under-treatment with less aggressive regimens.
Table1: Clinical and Demographic Characteristics
|
FL 3A |
FL 3b FL 3/ DLBCL |
|||
N=25 |
% |
N=21 |
% |
P |
|
Age |
0.45* |
||||
Mean+ SD |
61 ± 15.6 |
58 ± 11 |
|||
Range |
65 (19- 85) |
55 (39-80) |
|||
Gender |
0.56** |
||||
Male |
14 |
54% |
9 |
43% |
|
Female |
12 |
46% |
12 |
57% |
|
ECOG Performance Status |
1** |
||||
Good (ECOG 0,1) |
18 |
72% |
17 |
81% |
|
Poor (ECOG >1) |
2 |
8% |
1 |
5% |
|
Unknown |
5 |
20% |
3 |
14% |
|
B Symptoms |
0.74** |
||||
Present |
8 |
32% |
5 |
24% |
|
Not Present |
17 |
68% |
16 |
76% |
|
BM Involvement |
0.47** |
||||
Involved |
6 |
24% |
3 |
14% |
|
Not Involved |
16 |
64% |
16 |
76% |
|
Unknown |
3 |
12% |
2 |
10% |
|
Stage |
0.76** |
||||
I, II, III |
17 |
68% |
13 |
62% |
|
IV |
8 |
32% |
8 |
38% |
|
1st Line Regimen |
1** |
||||
R-CHOP) |
22 |
88% |
18 |
85% |
|
Other |
3 |
12% |
2 |
9% |
|
Median/Average Follow-up (Months) |
|||||
From DX |
54/60 |
62/65 |
0.68* |
||
From TX |
55/58 |
|
59/56 |
|
0.91* |
* Anova |
|||||
** Fisher's Exact |
Disclosures: Hill: Seattle Genetics: Honoraria , Membership on an entity’s Board of Directors or advisory committees ; Pfizer: Consultancy , Honoraria , Membership on an entity’s Board of Directors or advisory committees ; Janssen: Honoraria , Membership on an entity’s Board of Directors or advisory committees ; Celgene: Honoraria , Membership on an entity’s Board of Directors or advisory committees . Smith: celegene, spectrum, genentech: Honoraria .
See more of: Lymphoma: Chemotherapy, excluding Pre-Clinical Models
See more of: Oral and Poster Abstracts
*signifies non-member of ASH